サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1279849

急性骨髄性白血病の世界市場規模の調査・予測：化学療法別（シタラビン、アントラサイクリン系薬剤、アルキル化剤、代謝拮抗薬、チロシンキナーゼ阻害剤、ホルモン療法、その他の化学療法）、地域別分析、2023-2030年

Global Acute Myeloid Leukemia Market Size Study & Forecast, By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy, Other Chemotherapies), and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
急性骨髄性白血病の世界市場規模の調査・予測：化学療法別（シタラビン、アントラサイクリン系薬剤、アルキル化剤、代謝拮抗薬、チロシンキナーゼ阻害剤、ホルモン療法、その他の化学療法）、地域別分析、2023-2030年
出版日: 2023年05月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

急性骨髄性白血病（AML）は、血液がんの一種で、骨髄に未熟な白血球が過剰に存在するものです。

感染症と戦う役割を担う白血球の一種である未熟な骨髄球が急速に増殖することが特徴です。AMLではこの未熟な細胞が骨髄にたまり、健康な血液細胞の形成を阻害するため、症状やトラブルが発生します。急性骨髄性白血病の有病率の増加、新規治療法のイントロダクションの増加、精密医療の重視、免疫療法の採用の急増、医療費の増加は、全世界の市場需要の主な要因となっています。

また、老年人口の増加が、世界の市場成長の触媒として作用しています。米国がん協会によると、AMLは通常、高齢者の間で発生し、45歳以前はまれです。また、AMLの平均年齢は約68歳です。世界保健機関（WHO）の報告によると、高齢者の数は2020年の10億人から2030年には15億人に増加し、世界では60歳以上の6人に1人が高齢者になると予測されています。したがって、急速に増加する老年人口は、急性骨髄性白血病に罹患しやすく、市場成長のための有利な機会を創出しています。さらに、薬学や分子生物学の進歩による医薬品開発の促進や、研究開発への投資の増加は、予測期間中に様々な有利な機会をもたらしています。例えば、2022年5月、FDAはTibsovo, Servier Pharmaceuticals LLCのイボシデニブをアザシチジンと混合したもの（注射用アザシチジン）を新規診断の急性骨髄性白血病（AML）に対して承認したと宣言しました。さらに、これには、75歳以上の成人または集中的な導入化学療法を妨げる併存疾患を有する成人を対象としたFDAが承認した検査で確認された、感受性の高いIDH1変異が含まれています。しかし、薬剤に関する厳しい規制や化学療法に関連する合併症が、2023年から2030年の予測期間を通じて市場の成長を制限しています。

急性骨髄性白血病の世界市場の調査において考慮された主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、急性骨髄性白血病患者の増加、技術的進歩の高まり、患者中心のアプローチへの注目の高まりにより、2022年の市場を独占しています。米国がん協会によると、2023年には白血病の新規症例が約59,610件、白血病による死亡が23,710件記録されました。一方、アジア太平洋地域は、政府の積極的な取り組み、臨床試験の実施数の増加、ヘルスケア支出の増加、分子診断の進歩の拡大などの要因により、予測期間中に最も高いCAGRで成長すると予想されます。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することにあります。本レポートは、調査対象国の産業の質的・量的な側面を取り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界市場・セグメント別市場推計・予測、2020年～2030年
    • 急性骨髄性白血病市場、地域別、2020-2030年
    • 急性骨髄性白血病の市場：化学療法別、2020-2030年
  • 主要動向
  • 調査手法
  • 調査の前提条件

第2章 急性骨髄性白血病の世界市場の定義と範囲

  • 調査目的
  • 市場の定義とスコープ
    • 産業の進化
    • 本調査の対象範囲
  • 調査対象年
  • 通貨換算レート

第3章 急性骨髄性白血病の世界市場力学

  • 急性骨髄性白血病の市場インパクト分析（2020年～2030年）
    • 市場促進要因
      • 急性骨髄性白血病の有病率の増加
      • 老年人口の増加
    • 市場の課題
      • 医薬品に対する厳しい規制
      • 化学療法に関連する合併症
    • 市場機会
      • 薬理学および分子生物学の進歩別医薬品開発の促進
      • 研究開発への投資拡大

第4章 急性骨髄性白血病の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースインパクト分析
  • PEST分析
    • 政治的
    • 経済的
    • 社会的
    • 技術的
    • 環境
    • 法律
  • トップ投資機会
  • 主要成功戦略
  • COVID-19影響度分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの提言・結論

第5章 急性骨髄性白血病の世界市場：化学療法別

  • 市場スナップショット
  • 急性骨髄性白血病の世界市場：化学療法別、業績-ポテンシャル分析
  • 急性骨髄性白血病の世界市場、化学療法別推定・予測2020～2030年
  • 急性骨髄性白血病市場、サブセグメント別分析
    • シタラビン
    • アントラサイクリン系薬剤
    • アルキル化剤
    • 代謝拮抗薬
    • チロシンキナーゼ阻害剤
    • ホルモン療法
    • その他の化学療法

第6章 急性骨髄性白血病の世界市場：地域別分析

  • 上位の主要国
  • 上位新興国
  • 急性骨髄性白血病市場の地域別市場スナップショット
  • 北米
    • 米国
      • 化学療法別の推定・予測、2020～2030年
    • カナダ
  • 欧州急性骨髄性白血病市場のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域の急性骨髄性白血病市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ急性骨髄性白血病市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ地域
    • サウジアラビア
    • 南アフリカ共和国
    • その他中東とアフリカ

第7章 競合情報

  • 主要企業のSWOT分析
  • トップ市場戦略
  • 企業プロファイル
    • Novartis AG
      • 主要情報
      • 概要
      • 財務情報（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の動向
    • Genmab AS
    • Otsuka Holdings Co. Ltd
    • Sanofi-Aventis（Genzyme Corporation）
    • Teva Pharmaceutical Industries Ltd.（Cephalon Inc.）
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Sunesis Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • Oncolyze Inc.

第8章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Acute Myeloid Leukemia Market, report scope
  • TABLE 2. Global Acute Myeloid Leukemia Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Acute Myeloid Leukemia Market estimates & forecasts by Chemotherapy 2020-2030 (USD Billion)
  • TABLE 4. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 5. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Acute Myeloid Leukemia Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Acute Myeloid Leukemia Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. U.S. Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 16. U.S. Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. Canada Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. UK Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 21. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. Germany Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 24. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. France Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 27. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. Italy Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 30. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Spain Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 33. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. RoE Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 36. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. China Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 39. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. India Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 42. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. Japan Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 45. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. South Korea Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 48. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. Australia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 51. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. Brazil Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 57. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Mexico Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 60. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. RoLA Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 63. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. Saudi Arabia Acute Myeloid Leukemia Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 66. South Africa Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoMEA Acute Myeloid Leukemia Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Acute Myeloid Leukemia Market
  • TABLE 69. List of primary sources, used in the study of global Acute Myeloid Leukemia Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Acute Myeloid Leukemia Market, research methodology
  • FIG 2. Global Acute Myeloid Leukemia Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Acute Myeloid Leukemia Market, key trends 2022
  • FIG 5. Global Acute Myeloid Leukemia Market, growth prospects 2023-2030
  • FIG 6. Global Acute Myeloid Leukemia Market, porters 5 force model
  • FIG 7. Global Acute Myeloid Leukemia Market, pest analysis
  • FIG 8. Global Acute Myeloid Leukemia Market, value chain analysis
  • FIG 9. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Acute Myeloid Leukemia Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Acute Myeloid Leukemia Market, regional snapshot 2020 & 2030
  • FIG 15. North America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Acute Myeloid Leukemia Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Acute Myeloid Leukemia Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Acute Myeloid Leukemia (AML) is a form of blood cancer and bone marrow with excess immature white blood cells. It is characterized by the rapid proliferation of immature myeloid cells, which are a type of white blood cell responsible for fighting infections. These immature cells amass in the bone marrow in AML and obstruct the formation of healthy blood cells, resulting in symptoms and problems. The increasing prevalence of acute myeloid leukemia, the rising introduction of novel therapies, the rising emphasis on precision medicine, the surging adoption of immunotherapies, and increasing healthcare expenditure are the primary factors that are attributing to the market demand across the globe.

In addition, the rising geriatric population is acting as a catalyzing factor for market growth across the globe. According to the American Cancer Society, AML is usually occurred among the older population and is uncommon before the age of 45. Also, the average age for AML is nearly 68. The World Health Organization (WHO) reported that it is anticipated that the number of aging people increase from 1 billion in 2020 to 1.5 billion in 2030 which worldwide accounts for 1 in 6 people above 60. Hence, the rapidly growing geriatric population is more prone to be affected by acute myeloid leukemia, which is creating lucrative opportunities for market growth. Moreover, rising advancements in pharmacology and molecular biology to promote drug development, as well as the increasing investments in research and development are presenting various lucrative opportunities over the forecasting years. For instance, in May 2022, the FDA declared that they approved Tibsovo, Servier Pharmaceuticals LLC's ivosidenib in a mixture with azacitidine (azacitidine for injection) for novel diagnosed acute myeloid leukemia (AML). Additionally, it involves a susceptible IDH1 mutation identified by an FDA-approved test in adults aged 75 years and over or with comorbidities that prevent intensive induction chemotherapy. However, the stringent regulations on drugs and complications related to chemotherapy are restricting the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Acute Myeloid Leukemia Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing incidences of acute myeloid leukemia cases, rising technological advancements, and growing focus on patient-centric approaches. The American Cancer Society stated that in 2023, approximately 59,610 new cases of leukemia and 23,710 deaths from leukemia were recorded. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as favorable government initiatives, an increasing number of clinical trials conducted, rising healthcare expenditure, and growing advancements in molecular diagnostics.

Major market players included in this report are:

  • Novartis AG
  • Genmab AS
  • Otsuka Holdings Co. Ltd
  • Sanofi-Aventis (Genzyme Corporation)
  • Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sunesis Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Oncolyze Inc.

Recent Developments in the Market:

  • In January 2022, Oncolyze announced that OM-301, a medication used to treat acute myeloid leukaemia (AML), had been granted FDA orphan drug designation.
  • In December 2021, SNDX-5613, a highly specific oral menin inhibitor for the treatment of acute myeloid leukaemia (AML), was approved as an orphan drug by the European Commission.

Global Acute Myeloid Leukemia Market Report Scope:

  • Historical Data: - 2020 - 2021
  • Base Year for Estimation: - 2022
  • Forecast period: - 2023-2030
  • Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: - Chemotherapy, Region
  • Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Chemotherapy:

  • Cytarabine
  • Anthracycline Drugs
  • Alkylating Agents
  • Anti-metabolites
  • Tyrosine Kinase Inhibitors
  • Hormonal Therapy
  • Other Chemotherapies

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Acute Myeloid Leukemia Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Acute Myeloid Leukemia Market, by Chemotherapy, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Acute Myeloid Leukemia Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Acute Myeloid Leukemia Market Dynamics

  • 3.1. Acute Myeloid Leukemia Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of acute myeloid leukemia
      • 3.1.1.2. Rising geriatric population
    • 3.1.2. Market Challenges
      • 3.1.2.1. Stringent regulations on drugs
      • 3.1.2.2. Complications related to chemotherapy
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising advancements in pharmacology and molecular biology to promote drug development
      • 3.1.3.2. Increasing investments in research and development

Chapter 4. Global Acute Myeloid Leukemia Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Acute Myeloid Leukemia Market, by Chemotherapy

  • 5.1. Market Snapshot
  • 5.2. Global Acute Myeloid Leukemia Market by Chemotherapy, Performance - Potential Analysis
  • 5.3. Global Acute Myeloid Leukemia Market Estimates & Forecasts by Chemotherapy 2020-2030 (USD Billion)
  • 5.4. Acute Myeloid Leukemia Market, Sub Segment Analysis
    • 5.4.1. Cytarabine
    • 5.4.2. Anthracycline Drugs
    • 5.4.3. Alkylating Agents
    • 5.4.4. Anti-metabolites
    • 5.4.5. Tyrosine Kinase Inhibitors
    • 5.4.6. Hormonal Therapy
    • 5.4.7. Other Chemotherapies

Chapter 6. Global Acute Myeloid Leukemia Market, Regional Analysis

  • 6.1. Top Leading Countries
  • 6.2. Top Emerging Countries
  • 6.3. Acute Myeloid Leukemia Market, Regional Market Snapshot
  • 6.4. North America Acute Myeloid Leukemia Market
    • 6.4.1. U.S. Acute Myeloid Leukemia Market
      • 6.4.1.1. Chemotherapy breakdown estimates & forecasts, 2020-2030
    • 6.4.2. Canada Acute Myeloid Leukemia Market
  • 6.5. Europe Acute Myeloid Leukemia Market Snapshot
    • 6.5.1. U.K. Acute Myeloid Leukemia Market
    • 6.5.2. Germany Acute Myeloid Leukemia Market
    • 6.5.3. France Acute Myeloid Leukemia Market
    • 6.5.4. Spain Acute Myeloid Leukemia Market
    • 6.5.5. Italy Acute Myeloid Leukemia Market
    • 6.5.6. Rest of Europe Acute Myeloid Leukemia Market
  • 6.6. Asia-Pacific Acute Myeloid Leukemia Market Snapshot
    • 6.6.1. China Acute Myeloid Leukemia Market
    • 6.6.2. India Acute Myeloid Leukemia Market
    • 6.6.3. Japan Acute Myeloid Leukemia Market
    • 6.6.4. Australia Acute Myeloid Leukemia Market
    • 6.6.5. South Korea Acute Myeloid Leukemia Market
    • 6.6.6. Rest of Asia Pacific Acute Myeloid Leukemia Market
  • 6.7. Latin America Acute Myeloid Leukemia Market Snapshot
    • 6.7.1. Brazil Acute Myeloid Leukemia Market
    • 6.7.2. Mexico Acute Myeloid Leukemia Market
  • 6.8. Middle East & Africa Acute Myeloid Leukemia Market
    • 6.8.1. Saudi Arabia Acute Myeloid Leukemia Market
    • 6.8.2. South Africa Acute Myeloid Leukemia Market
    • 6.8.3. Rest of Middle East & Africa Acute Myeloid Leukemia Market

Chapter 7. Competitive Intelligence

  • 7.1. Key Company SWOT Analysis
    • 7.1.1. Company 1
    • 7.1.2. Company 2
    • 7.1.3. Company 3
  • 7.2. Top Market Strategies
  • 7.3. Company Profiles
    • 7.3.1. Novartis AG
      • 7.3.1.1. Key Information
      • 7.3.1.2. Overview
      • 7.3.1.3. Financial (Subject to Data Availability)
      • 7.3.1.4. Product Summary
      • 7.3.1.5. Recent Developments
    • 7.3.2. Genmab AS
    • 7.3.3. Otsuka Holdings Co. Ltd
    • 7.3.4. Sanofi-Aventis (Genzyme Corporation)
    • 7.3.5. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
    • 7.3.6. Pfizer Inc.
    • 7.3.7. F. Hoffmann-La Roche Ltd
    • 7.3.8. Sunesis Pharmaceuticals Inc.
    • 7.3.9. Astellas Pharma Inc.
    • 7.3.10. Oncolyze Inc.

Chapter 8. Research Process

  • 8.1. Research Process
    • 8.1.1. Data Mining
    • 8.1.2. Analysis
    • 8.1.3. Market Estimation
    • 8.1.4. Validation
    • 8.1.5. Publishing
  • 8.2. Research Attributes
  • 8.3. Research Assumption